Amelioration of Dextran Sodium Sulfate-Induced Colitis in Mice through Oral Administration of Palmitoylethanolamide

Purvi Trivedi,Tanya Myers,Bithika Ray,Matthew Allain,Juan Zhou,Melanie Kelly,Christian Lehmann
DOI: https://doi.org/10.3390/biomedicines12051000
IF: 4.757
2024-05-03
Biomedicines
Abstract:Inflammatory bowel disease (IBD) is a group of chronic disorders characterized by pain, ulceration, and the inflammation of the gastrointestinal tract (GIT) and categorized into two major subtypes: ulcerative colitis (UC) and Crohn's disease. The inflammation in UC is typically restricted to the mucosal surface, beginning in the rectum and extending through the entire colon. UC patients typically show increased levels of pro-inflammatory cytokines, leading to intestinal epithelial apoptosis and mucosal inflammation, which impair barrier integrity. Chronic inflammation is associated with the rapid recruitment and inappropriate retention of leukocytes at the site of inflammation, further amplifying the inflammation. While UC can be managed using a number of treatments, these drugs are expensive and cause unwanted side effects. Therefore, a safe and effective treatment for UC patients is needed. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide and an analog of the endocannabinoid anandamine. PEA administration has been found to normalize intestinal GIT motility and reduce injury in rodents and humans. In the current study, we examined the efficacy of PEA encapsulated in phytosomes following oral administration in experimental ulcerative colitis. Here, we showed that PEA at a human-equivalent dose of 123 mg/kg (OD or BID) attenuated DSS-induced experimental colitis as represented by the reduction in clinical signs of colitis, reduction in gross mucosal injury, and suppression of leukocyte recruitment at inflamed venules. These findings add to the growing body of data demonstrating the beneficial effects of PEA to control the acute phase of intestinal inflammation occurring during UC.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the efficacy of palmitoylethanolamide (PEA) in the treatment of experimental ulcerative colitis (UC). Specifically, the researchers evaluated the improvement effect of PEA encapsulated in plants on dextran sodium sulfate (DSS) - induced colitis in mice by oral administration. The study focused on whether PEA could alleviate the clinical symptoms of DSS - induced colitis, reduce colonic mucosal damage, and inhibit leukocyte recruitment at the inflamed sites. It is mentioned in the paper that ulcerative colitis is a chronic disease characterized by intestinal inflammation, mainly affecting the colonic mucosal layer, resulting in pain, ulcers and inflammation. Although the current drugs used to treat UC are effective, they have the problems of high cost and large side effects. Therefore, it is very necessary to find a safe and effective treatment method for UC. As an endogenous fatty acid amide, PEA has been found to normalize intestinal motility and reduce intestinal damage caused by ischemia - reperfusion. However, there is still insufficient research on whether PEA can relieve the symptoms of UC, especially in the mouse model. This study aims to fill this gap and evaluate the potential therapeutic role of PEA in the DSS - induced colitis model.